0000315066-16-006030.txt : 20160808 0000315066-16-006030.hdr.sgml : 20160808 20160808172917 ACCESSION NUMBER: 0000315066-16-006030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160804 FILED AS OF DATE: 20160808 DATE AS OF CHANGE: 20160808 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Coherus BioSciences, Inc. CENTRAL INDEX KEY: 0001512762 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273615821 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 649-3530 MAIL ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: BioGenerics, Inc. DATE OF NAME CHANGE: 20110210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36721 FILM NUMBER: 161815330 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2016-08-04 0 0001512762 Coherus BioSciences, Inc. CHRS 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 1 1 See Remark 1 Common Stock 2016-08-04 4 S 0 23200 28.16 D 486994 I See footnote Common Stock 2016-08-04 4 S 0 200 27.97 D 486794 I See footnote Common Stock 2016-08-04 4 S 0 100 27.87 D 486694 I See footnote Common Stock 2016-08-04 4 S 0 100 27.95 D 486594 I See footnote Common Stock 2016-08-05 4 S 0 25000 28.78 D 461594 I See footnote By F-Prime Capital Partners Healthcare Fund III LP (109,478 shares of Common Stock), Impresa Fund III Limited Partnership (351,588 shares of Common Stock) and F-Prime Inc. (528 shares of Common Stock). The general partner of F-Prime Capital Partners Healthcare Fund III LP is F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA). FPCPHA and Impresa Fund III Limited Partnership are each solely managed by Impresa Management LLC, their general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $27.93 to $28.29. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $27.95 to $28.00. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $27.87 to $27.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.71 to $28.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Remark 1: Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: FMR Co., Inc. (FMRC), an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and Fidelity Institutional Asset Management Trust Company (FIAMTC), an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, are the beneficial owners of Common Stock of Coherus Biosciences Inc. as a result of acting as investment adviser to various client funds and accounts. FMR LLC and Abigail P. Johnson have no pecuniary interest in the Common Stock beneficially owned by FMRC and FIAMTC. Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2016-08-08